Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to -$287490.0.

  • SAB Biotherapeutics' Change in Accured Expenses fell 11549.3% to -$287490.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$103750.0, marking a year-over-year decrease of 10643.65%. This contributed to the annual value of -$1.2 million for FY2024, which is 2820.89% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Change in Accured Expenses of -$287490.0 as of Q3 2025, which was down 11549.3% from $1.0 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Change in Accured Expenses high stood at $3.0 million for Q1 2021, and its period low was -$2.0 million during Q2 2022.
  • Its 5-year average for Change in Accured Expenses is -$40143.1, with a median of -$287490.0 in 2025.
  • As far as peak fluctuations go, SAB Biotherapeutics' Change in Accured Expenses skyrocketed by 2251284.78% in 2021, and later tumbled by 26524.28% in 2023.
  • Over the past 5 years, SAB Biotherapeutics' Change in Accured Expenses (Quarter) stood at $276329.0 in 2021, then plummeted by 215.89% to -$320231.0 in 2022, then surged by 538.06% to $1.4 million in 2023, then tumbled by 202.66% to -$1.4 million in 2024, then surged by 80.04% to -$287490.0 in 2025.
  • Its Change in Accured Expenses was -$287490.0 in Q3 2025, compared to $1.0 million in Q2 2025 and $583073.0 in Q1 2025.